Centre d'Esclerosi Múltiple de Catalunya

Recent papers from Centre d'Esclerosi Múltiple de Catalunya

1. Cognitive Resilience and Improvements in Health-Related Quality of Life Over 4 Years in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results from the CLARIFY-MS Extension StudyMultiple Sclerosis and Related Disorders · 2026
2. Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension studyMultiple Sclerosis Journal · 2026
3. Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 yearsMultiple Sclerosis and Related Disorders · 2026
4. The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphomaBlood · 2025
5. Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trialsMultiple Sclerosis Journal · 2025
6. Comorbidities Are Associated With Unfavorable Outcome in Aquaporin‐4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease: Exploratory Study From the CROCTINO CohortEuropean Journal of Neurology · 2025
7. Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?Multiple Sclerosis Journal · 2025
8. Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD studyJournal of Neurology Neurosurgery & Psychiatry · 2025
9. Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-ObstructionNeurology Neuroimmunology & Neuroinflammation · 2025
10. Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyFrontiers in Immunology · 2025
11. Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of ImmunosenescenceAging Cell · 2025
12. Efficacy of cognitive rehabilitation in cognition and brain networks: A randomised clinical trial in patients with multiple sclerosisNeuroImage Clinical · 2025
13. Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohortMultiple Sclerosis Journal · 2024
14. IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune EncephalomyelitisInternational Journal of Molecular Sciences · 2024
15. Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis (S31.003)Neurology · 2024
16. Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014)Neurology · 2024
17. B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights from ASCLEPIOS I and II Trials (P9-6.002)Neurology · 2024
18. Importance of Bodily Functions in Neuromyelitis Optica Spectrum Disorder from Neurologists’ Perspective (P10-14.018)Neurology · 2024
19. Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study (P1-6.010)Neurology · 2024
20. Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial (P2-6.007)Neurology · 2024